The prevalence of Hepatitis C virus (HCV) is approximately 3% around the world. This virus causes chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. The effectiveness of interferon-α and ribavirin therapy is about 50% and is associated with significant toxicity and cost. Hence, generating new vaccines or drugs is an obligation. However, there is no vaccine available for clinical use. DNA vaccines have some advantages such as producing feasibility and generating intensive cellular and humoral immune responses. Activation and improvement of natural immune defense mechanisms is a necessity for the development of an effective HCV vaccine. This article discusses the current status of therapies for hepatitis C, the promising new therapies and the experimental strategies to develop an HCV vaccine.
experience (6) . However, toxicity is very important in any experimental therapeutic agent (7) . The chronic stage of infection is mainly related to HCV pathogenicity, hence there is a need to improve the ability of a vaccine approach to manage or treat this infection (5) . Combination of pegylated interferon (IFN) and ribavirin is the common treatment for HCV. Since this regimen is costly, extended, have severe side-effects and is not efficient sometimes (8) . On the other hand, recently researchers have shown that tamoxifen suppressed HCV genome replication in a dose dependent manner (9).
However, there are crucial issues concerning generating HCV vaccines that will have the ability to prevent and/ or treat this infection (10) . In this review, we will first demonstrate the current understanding of HCV infection, pathogenicity and therapy methods and then focus our attention on the significant degree of viral diversity which complicates vaccine development.
Molecular analysis of the HCV genome
The HCV genome is a single-stranded RNA which contains a large open reading frame of 9, 030 to 9, 099 bp that could encode a polyprotein of 3, 010 to 3, 033 amino acids (10) (11) (12) . Polyprotein cleavage and separate protein production occurs at two sites via host signal peptidase in the structural region and HCV-encoded proteases in the nonstructural (NS) region. The structural region is composed of the core protein and two envelope proteins (E1 and E2) (11) . The defined and hypothetical properties of these genomic proteins are shown in Table 1 .
The HCV core protein consists of the first structural protein at the amino end of the polyprotein, and performs several activities (13) (14) . Protease activity NS3/NS4A Serine protease activity E1 and E2
Glycoproteins of envelope interact with or affect the host cell functions (23) . 
